Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinxing Mihuan oral solution is a modernized traditional Chinese medicine (mTCM) compound preparation composed of Ginkgo biloba extract (GBE) and Armillariella mellea (also known as Armillaria mellea) powder. It is widely used in China for the treatment of cardiovascular and cerebrovascular diseases, including coronary heart disease, angina pectoris, and ischemic stroke. The ginkgo leaf extract promotes blood circulation, removes blood stasis, and unblocks collaterals, while Armillariella mellea powder has sedative and neuroprotective effects. The combination exhibits synergistic antioxidant, anti-inflammatory, and vascular-regulating properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinxing Mihuan oral solution.